Wei Yao

机构：Sino Biopharmaceutical (China), Evive Biotech (China), Shanxi Datong University · ORCID：0009-0007-5489-239X

发表论文 8 篇 · 总被引 45 次 · h-index 4

代表论文

• A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer (2024 · BMC Cancer · 被引 18)
• Development and validation of machine-learning models for the difficulty of retroperitoneal laparoscopic adrenalectomy based on radiomics (2023 · Frontiers in Endocrinology · 被引 10)
• A nomogram for evaluation and analysis of difficulty in retroperitoneal laparoscopic adrenalectomy: A single-center study with prospective validation using LASSO-logistic regression (2022 · Frontiers in Endocrinology · 被引 10)
• Development and validation of nomograms to predict survival of primary adrenal lymphoma: a population-based retrospective study (2023 · Scientific Reports · 被引 4)
• Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label Trial (2025 · Clinical Drug Investigation · 被引 2)
• An interpretable clinical-radiomics-deep learning model based on magnetic resonance imaging for predicting postoperative Gleason grading in prostate cancer: a dual-center study (2025 · Frontiers in Oncology · 被引 2)